AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use

AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use

Submitted by admin on September 12, 2023 - 7:10pm
Source: 
Fierce Pharma
News Tags: 
AstraZeneca
Fasenra
clinical trials
GSK
Nucala
eosinophilic asthma
Headline: 
AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's Nucala in new use
snippet: 

Competing to treat patients with severe eosinophilic asthma (SEA), AstraZeneca has fared well matching its IL-5 inhibitor Fasenra up against GSK’s Nucala.

Do Not Allow Advertisers to Use My Personal information